160 related articles for article (PubMed ID: 16192494)
1. JAK2 mutations in myeloproliferative disorders.
Tefferi A; Lasho TL; Gilliland G
N Engl J Med; 2005 Sep; 353(13):1416-7; author reply 1416-7. PubMed ID: 16192494
[No Abstract] [Full Text] [Related]
2. A gain-of-function mutation of JAK2 in myeloproliferative disorders.
Kralovics R; Passamonti F; Buser AS; Teo SS; Tiedt R; Passweg JR; Tichelli A; Cazzola M; Skoda RC
N Engl J Med; 2005 Apr; 352(17):1779-90. PubMed ID: 15858187
[TBL] [Abstract][Full Text] [Related]
3. [New molecular markers within the chronic myeloproliferative disorders. II: the JAK2 mutation].
Larsen TS; Pallisgaard N; Christensen JH; Gram-Hansen P; Kerndrup GB; Møller MB; Hasselbalch HC
Ugeskr Laeger; 2006 Sep; 168(39):3299-303. PubMed ID: 17032592
[TBL] [Abstract][Full Text] [Related]
4. A case of myelofibrosis with myeloid metaplasia with JAK2(V617F) mutation who developed fibrous tumours in multiple organs.
Tabuchi T; Ohashi H; Fukami S; Susaki N; Kunishima S; Yokozawa T; Nagai H; Moritani S; Ichihara S; Saito H; Hamaguchi M
Eur J Haematol; 2006 Sep; 77(3):264-6. PubMed ID: 16923114
[No Abstract] [Full Text] [Related]
5. The JAK2(V617F) tyrosine kinase mutation in myelofibrosis with myeloid metaplasia: lineage specificity and clinical correlates.
Tefferi A; Lasho TL; Schwager SM; Steensma DP; Mesa RA; Li CY; Wadleigh M; Gary Gilliland D
Br J Haematol; 2005 Nov; 131(3):320-8. PubMed ID: 16225651
[TBL] [Abstract][Full Text] [Related]
6. A unifying mutation in chronic myeloproliferative disorders.
Goldman JM
N Engl J Med; 2005 Apr; 352(17):1744-6. PubMed ID: 15858182
[No Abstract] [Full Text] [Related]
7. JAKing up hematopoietic proliferation.
Shannon K; Van Etten RA
Cancer Cell; 2005 Apr; 7(4):291-3. PubMed ID: 15837617
[TBL] [Abstract][Full Text] [Related]
8. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders.
Baxter EJ; Scott LM; Campbell PJ; East C; Fourouclas N; Swanton S; Vassiliou GS; Bench AJ; Boyd EM; Curtin N; Scott MA; Erber WN; Green AR;
Lancet; 2005 Mar 19-25; 365(9464):1054-61. PubMed ID: 15781101
[TBL] [Abstract][Full Text] [Related]
9. Methods for the detection of the JAK2 V617F mutation in human myeloproliferative disorders.
Campbell PJ; Scott LM; Baxter EJ; Bench AJ; Green AR; Erber WN
Methods Mol Med; 2006; 125():253-64. PubMed ID: 16502590
[TBL] [Abstract][Full Text] [Related]
10. Occurrence of the JAK2 V617F mutation in the WHO provisional entity: myelodysplastic/myeloproliferative disease, unclassifiable-refractory anemia with ringed sideroblasts associated with marked thrombocytosis.
Remacha AF; Nomdedéu JF; Puget G; Estivill C; Sarda MP; Canals C; Aventin A
Haematologica; 2006 May; 91(5):719-20. PubMed ID: 16670082
[TBL] [Abstract][Full Text] [Related]
11. Narrative review: Thrombocytosis, polycythemia vera, and JAK2 mutations: The phenotypic mimicry of chronic myeloproliferation.
Spivak JL
Ann Intern Med; 2010 Mar; 152(5):300-6. PubMed ID: 20194236
[TBL] [Abstract][Full Text] [Related]
12. The lack of association between JAK2 V617F mutation and myelodysplastic syndrome with or without myelofibrosis.
Yip SF; So CC; Chan AY; Liu HY; Wan TsK; Chan LC
Leukemia; 2006 Jun; 20(6):1165. PubMed ID: 16572200
[No Abstract] [Full Text] [Related]
13. [Novel method in diagnosis of chronic myeloproliferative disorders--detection of JAK2 mutation].
Rajnai H; Bödör C; Reiniger L; Timár B; Csernus B; Szepesi A; Csomor J; Matolcsy A
Orv Hetil; 2006 Nov; 147(45):2175-9. PubMed ID: 17402211
[TBL] [Abstract][Full Text] [Related]
14. JAK2 mutation in essential thrombocythaemia: clinical associations and long-term prognostic relevance.
Wolanskyj AP; Lasho TL; Schwager SM; McClure RF; Wadleigh M; Lee SJ; Gilliland DG; Tefferi A
Br J Haematol; 2005 Oct; 131(2):208-13. PubMed ID: 16197451
[TBL] [Abstract][Full Text] [Related]
15. Concomitant neutrophil JAK2 mutation screening and PRV-1 expression analysis in myeloproliferative disorders and secondary polycythaemia.
Tefferi A; Sirhan S; Lasho TL; Schwager SM; Li CY; Dingli D; Wolanskyj AP; Steensma DP; Mesa R; Gilliland DG
Br J Haematol; 2005 Oct; 131(2):166-71. PubMed ID: 16197445
[TBL] [Abstract][Full Text] [Related]
16. The V617F JAK2 mutation and the myeloproliferative disorders.
Percy MJ; McMullin MF
Hematol Oncol; 2005; 23(3-4):91-3. PubMed ID: 16285006
[TBL] [Abstract][Full Text] [Related]
17. Case 15-2006: the Budd-Chiari syndrome and V617F mutation in JAK2.
Spivak JL; Moliterno AR; Silver RT
N Engl J Med; 2006 Aug; 355(7):737; author reply 738. PubMed ID: 16914715
[No Abstract] [Full Text] [Related]
18. [Acquired mutation of JAK2 tyrosine kinase and polycythaemia vera].
Pargade V; Darnige L; Gaussem P
Ann Biol Clin (Paris); 2006; 64(1):3-9. PubMed ID: 16420986
[TBL] [Abstract][Full Text] [Related]
19. Polycythemia vera: scientific advances and current practice.
Tefferi A; Spivak JL
Semin Hematol; 2005 Oct; 42(4):206-20. PubMed ID: 16210034
[TBL] [Abstract][Full Text] [Related]
20. Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis.
Levine RL; Wadleigh M; Cools J; Ebert BL; Wernig G; Huntly BJ; Boggon TJ; Wlodarska I; Clark JJ; Moore S; Adelsperger J; Koo S; Lee JC; Gabriel S; Mercher T; D'Andrea A; Fröhling S; Döhner K; Marynen P; Vandenberghe P; Mesa RA; Tefferi A; Griffin JD; Eck MJ; Sellers WR; Meyerson M; Golub TR; Lee SJ; Gilliland DG
Cancer Cell; 2005 Apr; 7(4):387-97. PubMed ID: 15837627
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]